January 22, 2007 (Dallas, TX) – The largest-yet analysis of its kind supports the use of cardiac resynchronization therapy (CRT), either with or without defibrillator backup, in patients with NYHA ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved an expanded indication of self-administered subcutaneous furosemide for patients with HF. The ...
The NYHA classification was originally designed as a clinical and not a research tool. [7] It was never meant to serve the purpose of establishing the diagnosis of HF. It was designed purely as a ...
Please provide your email address to receive an email when new articles are posted on . Device-based therapy may be necessary for certain patients with NYHA class II/III heart failure with reduced ...
After a 12-month follow-up of patients in the CHAMP-HF registry, Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) was shown to be more prognostically accurate compared with New ...
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced findings from a global real-world evidence study that the risk of mortality increases with worse New York Heart ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback